Eton Pharmaceuticals, Inc. (ETON) Stock Score, Valuation & Financial Research
Eton Pharmaceuticals, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 35/100.
Quick answer for ETON
Eton Pharmaceuticals, Inc. currently has a Wall Street Score of 35/100. The stored market price is $57.62. Its financial score is 31/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Eton Pharmaceuticals, Inc. does
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON financial snapshot
- Wall Street Score:
- 35/100
- Current price:
- $57.62
- Market capitalization:
- $1.58B
- Revenue:
- $105.6M
- Net income:
- $12.7M
- Free cash flow:
- $10.2M
- Cash:
- $26.8M
- Total debt:
- $29.0M
- EPS:
- 0.47
- P/E ratio:
- 123.9x
- Financial score:
- 31/100
- Valuation score:
- 0/100
- Revenue score:
- 46/100
What stands out
- Reported year-over-year revenue growth is +0.3%.
- Free cash flow is $10.2M, showing positive cash generation.
- The balance sheet shows $26.8M of cash versus $29.0M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 31/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research ETON
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.